By staff writers

March 12, 2015 -- Sunnybrook Health Sciences Centre in Toronto and GE Healthcare have inked a deal to co-develop WaveCheck, an ultrasound tool designed to monitor breast cancer response to chemotherapy.

Making use of conventional ultrasound equipment, WaveCheck employs ultrasound to visually demonstrate if chemotherapy is destroying a breast cancer tumor, in as little as one week after treatment begins, according to Sunnybrook. The institution said that the ultrasound chemotherapy monitoring technology was invented, refined, and tested by Dr. Gregory Czarnota, chief of radiation oncology at Sunnybrook's Odette Cancer Centre, and Michael Kolios, professor of physics and associate dean of research and graduate studies at Ryerson University.

Clinical testing of WaveCheck is currently underway at Sunnybrook and MD Anderson Cancer Center in Houston; 20 Canadian and 20 U.S. women with locally advanced breast cancer are participating in the study.

The Sunnybrook/GE partnership was brokered by MaRS Innovation, a commercialization agent for Toronto universities.

GE launches products in MRI, ultrasound, HIT at ECR 2015
VIENNA - GE Healthcare is highlighting a pair of new MRI scanners, Signa Creator and Signa Explorer, making their global launch at this week's ECR 2015...
FDA issues massive recall of GE MRI scanners
The U.S. Food and Drug Administration has ordered a recall of thousands of MRI scanners manufactured by GE Healthcare to correct a problem that could...
GE plans multiple installs in Kuwait
GE Healthcare is scheduled to install several scanners in the near future at several hospitals in Kuwait.
GE Healthcare posts flat Q4 sales as profits dip
GE Healthcare reported flat revenues for the company's fourth quarter as segment profit dipped 4%. The company reported strong order growth in the U.S....
Volpara joins forces with GE
Volpara Solutions has signed on GE Healthcare as a distributor for its breast density and quantitative breast imaging software offerings.

Copyright © 2015